MAPK8IP2
C-Jun-amino-terminal kinase-interacting protein 2
Protein Summary
The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module. JIP2 inhibits IL1 beta-induced apoptosis in insulin-secreting cells. May function as a regulator of vesicle transport, through interactions with the JNK-signaling components and motor proteins (By similarity). This gene encodes a scaffold protein that is thought to be involved in the regulation of the c-Jun amino-terminal kinase signaling pathway. This protein has been shown to interact with and regulate the activity of MAPK8/JNK1 and MAP2K7/MKK7 kinases. [provided by RefSeq, Jun 2017]
- ENST00000329492
- ENSP00000330572
- ENSG00000008735
- IB2
- JIP2
- PRKM8IPL
- IB2
- IB-2
- JIP2
- PRKM8IPL
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological process | 0.81 | ||
tissue sample | 0.69 | ||
molecular function | 0.63 | ||
PubMedID | 0.61 | ||
hub protein | 0.53 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 118.22 (req: < 5)
Gene RIFs: 2 (req: <= 3)
Antibodies: 230 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 118.22 (req: >= 5)
Gene RIFs: 2 (req: > 3)
Antibodies: 230 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 23
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0